Merck (MSD outside North America) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences , through a subsidiary, for $36.00 per each share in cash or for a total equity price of nearly $1.35bn.
A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
The lead candidate of the company bomedemstat (IMG-7289) is an investigational, orally available inhibitor of lysine-specific demethylase 1 (LSD1).
At present, bomedemstat is being analysed in various Phase II clinical trials to treat myelofibrosis, essential thrombocythemia and polycythemia vera, apart from various other indications.
The Imago takeover will extend the growing haematology portfolio of Merck .
Merck president and CEO Robert Davis said: “We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve.
“This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of haematology.”
As per the deal, the acquisition subsidiary of Merck will be merged into Imago following closing.
The acquisition is anticipated to conclude in the first quarter of next year.
Imago BioSciences founder and CEO Dr Hugh Rienhoff said: “This agreement leverages Merck’s industry-leading clinical development expertise to maximise the therapeutic potential of bomedemstat while providing important value for shareholders.”
In October this year, Merck reported worldwide sales of $15bn in the third quarter (Q3) of 2022 as against $13.15bn in the year-ago quarter, indicating a rise of 14%.
Source: pharmaceutical-technology.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
